«У моего сына не было в анамнезе депрессии или других хронических заболеваний», — сообщила производителю препарата Propecia, компании Organon, мать пациента с PFS.
This is the first in a series of reports on young men whose deaths occurred in connection with finasteride. Recently, a number of such cases have been brought to the Post-Finasteride Syndrome Foundation by families seeking to ensure that the circumstances of their loved ones’ passing are not overlooked. By sharing medical records, correspondence, and personal accounts, they aim to alert physicians, pharmacists, regulators, and the public that the drug may be associated with severe and persistent neuropsychiatric symptoms. Because a causal link between finasteride and fatal outcomes remains disputed, cases like Jalan Lotfolahpour’s rarely undergo scrutiny in the court of public opinion. Instead, they surface only after death, fragmented across mostly non-public documents, before fading from view.
May 8, 2026
Dear Friends:
Around 8:15 a.m. on Sunday, February 23, 2025, a man later identified to police as Herr U. was driving down Schäfflestraße in the Riederwald district of Frankfurt, Germany. While approaching The Standing Café at the end of this quiet residential street, he caught sight of a man on a bench, hunched forward. Minutes later, having fetched a coffee and Brötchen, Herr U. was driving back up Schäfflestraße when he saw the same man, still hunched forward on the bench. So he pulled over.
While walking toward him, he called out, “Sir, are you OK?”
No response.
“Are you OK?” he said again.
Nothing.
Now just inches away, he noticed that the man’s hands were blue.
Herr U. called 112, Germany’s emergency services line. A dispatcher walked him through resuscitation efforts. At 8:22 a.m., paramedics pulled up and took over, laboring until 8:47 a.m.
But for Jalan Tifaine Lotfolahpour, it was too late. His toxicology report would paint a complex picture of what happened. The student at Goethe University Frankfurt had ingested a mix of opioids, sedatives, serotonin modulators, antihistamines, and psychostimulants.
The cumulative effect, medical examiner Stefanie Plenzig, MD, wrote in the autopsy, was central regulatory failure due to intoxication. Jalan’s brain had swollen so severely that it could no longer regulate his heart and lungs. “In the confidential section of the death certificate,” she added, “an undetermined manner of death is documented without a specified cause of death.”
Dr. Plenzig’s investigation could not determine the manner of death—whether the ingestion was accidental or intentional—nor identify a single cause among the cocktail of drugs that triggered his systemic collapse.
How did a 26-year-old math whiz with a zest for life, who also excelled at artistic and athletic pursuits, wind up perishing on a bench across from his flat one winter morning?
In contrast to the multi-factorial picture presented in the autopsy, his mother, Catherine Béroud, believes there’s a single underlying cause: finasteride. And she shared with us extensive documents that she believes are consistent with that account. Over a period of six years, according to medical records we reviewed, Jalan told at least 14 doctors that his worsening constellation of symptoms—from anxiety, depression, and insomnia to reduced psychomotor activity, restless legs syndrome, and impaired sphincter function—were attributable to the hair-loss medication currently taken by millions of men worldwide.
During that lengthy search for answers to his health crises, Jalan also reached out to the PFS Foundation, which is not a healthcare organization, and does not offer medical advice.
“I’m a 20-year-old student from Frankfurt who’s been suffering from PFS for at least two years now… In the end, I couldn’t find any doctor willing to help me, so I emailed you,” he wrote on February 13, 2019.
“I’m desperate.”
The Pre-Blue Angel
Born the youngest of three boys on September 14, 1998, in Frankfurt, Jalan moved through his school days with few academic or social difficulties. Mature beyond his years, he was both a close friend and effective mentor, making him popular among classmates at every grade level.
By the time he’d graduated from Gymnasium—Germany’s equivalent of middle and high school—he spoke French and English, played the piano and saxophone, excelled in handball, and even practiced kung fu.
Mathematics, however, was where he most clearly stood out. So strong was his performance in his final year of Gymnasium that Goethe University admitted him as a special student, allowing him to take his math classes there. He went on to beat out Goethe freshmen for the Deutschlandstipendium, a prestigious merit-based scholarship awarded by the German government, which paid him about $350 per month.
Yet despite his intellectual gifts, Jalan never considered himself above his peers. While working part-time as a math tutor, he inspired many of them, via the Rubik’s Cube, to explore concepts like group theory and algorithm design, just as he himself had not long before.
With others, he discussed philosophical works like The Myth of Sisyphus by Albert Camus, coming to share the French existentialist’s view that life is inherently meaningless, but meaning—and happiness—can be found in daily struggles.
When more than 200 fellow students turned out for Jalan’s funeral, many eager to pay tribute, no one was surprised.
“He rarely thought of himself, always working to help others,” Arian told the crowd. “He was very fair. He hated injustice.”
“In Jalan, I had a second brother who accompanied me through every phase of growing up,” said Mateo.
Perhaps the most fitting appreciation was delivered by Jalan’s one-time roommate. “From the coworker who helped me land my job, to the politically engaged young man who led passionate debates, to the comedian who sparked fits of laughter, to the confidant who saw me through hard times. That was Jalan,” said Qasim. “He didn’t just take part in my life, he shaped it.”
By many accounts, the Jalan of his late teens seemed destined to find success in whatever career he chose, and perhaps even make some original contributions to knowledge in his field. But during the years that followed, while double majoring in math and philosophy at Goethe, something went awry.
The Cabinet of Dr. Wyrobnik
On December 1, 2016, then-18-year-old Jalan took the U-Bahn—Germany’s subway system—from his family’s flat in Riederwald to the office of Jacques Wyrobnik, MD. It was his first-ever consultation with a dermatologist. He was there because he’d recently noticed his hair thinning at the front.
Dr. Wyrobnik diagnosed Jalan with androgenic alopecia. Then he prescribed finasteride, which the patient took daily, as directed.
Until extreme fatigue set in.
Until insomnia began disrupting his studies.
Until flu-like symptoms became regular occurrences.
At that point, about six months after starting the medication, Jalan quit for three days. And like many hundreds of finasteride patients before and after him reporting to the PFS Foundation, he soon “crashed.” That is to say, he experienced a sudden and severe worsening of his existing symptoms, alongside new ones.
“Depression and its common companions (brain-fog, severe headaches) plagued me,” Jalan wrote to the PFS Foundation in his email of February 13, 2019. “It started subliminally and increased in intensity over time.”
Still, he went back on finasteride—as directed. About a year later, he quit for another three days, crashing again soon after.
“My depression severely intensified, I developed tremors, and I began having suicidal thoughts,” Jalan said in the same email, not long after which he quit the drug for good.
In tandem with doing so, he raised concerns about finasteride with Dr. Wyrobnik. “I notified him of my adverse reactions and the drug’s risks. But he was not interested at all and denied any mistakes,” Jalan told us, again in his email.
On January 31, 2019, Dr. Wyrobnik made a note in Jalan’s chart. It was coded “BEM,” for Betriebliches Eingliederungsmanagement (workplace integration management), indicating Jalan had returned to school after a medical absence.
The note read: “No hair loss, side effect of finasteride: depression.”
Down the Magic Mountain
Unfortunately for Jalan, when Dr. Wyrobnik initially prescribed him finasteride in 2016, the product label contained no mention of persistent side effects or serious neuropsychiatric symptoms.
But on July 5, 2018, German drug-regulatory authority BfArM issued a Red Hand Letter (English) to doctors and pharmacists. Titled “Potential risks associated with the use of finasteride-containing medications (1 mg and 5 mg dosages), and recommendations to educate your patients,” it read, in part:
Patients should…be informed that, based on individual case reports, sexual dysfunction may persist for more than 10 years after discontinuation, [and] that mood changes (including depressive mood, depression and suicidal thoughts) have been reported… Last year, the product information and leaflet for the 1 mg dose of finasteride products changed an adverse reaction from “depressive mood” to “depression.” In addition, a warning label has been added… “[A]nxiety” is included as a new side effect… Health care professionals are required to report any suspected case of adverse reactions to the corresponding authorization holder.
According to Jalan’s chart, he was last prescribed finasteride by Dr. Wyrobnik on October 2, 2018, three months after the Red Hand Letter was issued, which raises such questions as:
• Was Dr. Wyrobnik aware of the Red Hand Letter while treating Jalan? If so, did he share it with Jalan?
• Did Dr. Wyrobnik report Jalan’s suspected ADRs to the drug’s marketing authorization holder?
On April 29, via email, we sought comment from Dr. Wyrobnik. A day later, he replied:
“I follow the instructions and recommendations of the Red Hand Letter. Among patients treated with finasteride 1 mg and 5 mg, I have not observed the described side effects.”
The Medicinal Metamorphosis
“I used to be very ambitious academically. I began taking university courses at age 16, while still in high school, and finished my A-level exams with excellent grades. But now I can’t imagine continuing to study since it’s already the third semester and I haven’t passed any tests. I’m losing hope.”
That, too, is an excerpt from Jalan’s 2019 email to the PFS Foundation. And just as we had to more than 1,000 desperate PFS patients before him—and have to nearly 3,000 others since—we promptly replied. We advised him to report his symptoms to the FDA and BfArM, directed him to our Medical Professionals page, informed him of our Patient Support program, and added him to our Newsroom feed—which includes a story on BfArM’s Red Hand Letter.
We also sent him links to three studies we sponsored that had been published to date, by researchers at Brigham and Women’s Hospital, Feinberg School of Medicine, and The University of Milano. That, while informing him of a fourth study in the works at Baylor College of Medicine, and of progress being made by Sage Therapeutics in bringing its neuroactive steroid product, zuranolone, to market as a treatment for major depressive disorders (MDDs).
Less than an hour later, Jalan wrote, “Thank you for the quick response and telling me that there’s still hope. I’ll do my best, meditate a lot, and show my doctors the studies you sent.”
Those doctors, in addition to Dr. Wyrobnik, and Jalan’s family physician, Komelius Nubert, MD, would come to include urologists, andrologists, endocrinologists, pulmonologists, otolaryngologists, and psychiatrists. Collectively, they would prescribe him 22 medications—from aripiprazole, for MDD, to sumatriptan, for migraine headaches.
Following are excerpts from Jalan’s charts between the fall of 2018 and the fall of 2024, during which he sought relief from numerous persistent ailments he believed were due to finasteride use—and told every MD as much.
• October 2018: In their referral response to Dr. Nubert, endocrinologists Dorothea Szczawinska, MD, and Martin Engelbach, MD, wrote:
Patient reports fatigue, lack of motivation, sensitivity to cold, and depression. External treatment with finasteride 1 mg per day was prescribed for hair loss. This resulted in improvement of symptoms… Increased sleep cravings and difficulty sleeping through the night were also reported. Surgery is planned for nasal septum problems. Assessment and Recommendation: In summary, no endocrinological cause can currently be found for the symptoms reported in his medical history. In the case of externally diagnosed androgenic alopecia, treatment with finasteride can continue as before.
On April 29, via email, we sought comment from Dr. Engelbach, specifically asking:
In light of the European Medicines Agency’s 2025 ruling that finasteride can cause suicidal thoughts—along with similar clinical and epidemiological data that has emerged since 2018—would you today advise a patient like Jalan, who reports symptoms consistent with PFS, to continue taking finasteride? If so, why?
At press time, Dr. Engelbach had not responded to our query.
• April 2019: In his referral response to GP Ilja Kleiman, MD, neurologist and psychiatrist Vladimir Sirkis, MD, wrote:
Current Diagnosis: Suspected Somatic Depression. History: He has been ill for a year. He has been experiencing bouts of fatigue for about three months. He can’t fall asleep… He snores… He was previously given finasteride for hair loss. He has become depressed. Finasteride has been discontinued. He cannot tolerate citalopram [used to treat MDD]. Currently no medication. No drugs. Cannabis irregular. Lab tests are normal. Summary and assessment: Neurological findings unremarkable… Exclusion of sleep apnea syndrome is recommended. Mirtazapine [a serotonergic antidepressant used to treat MDD] prescribed for sleep regulation. Cannabis discouraged.
• July 2019: Uwe Holler, MD, an internist specializing in preventive and men’s health, wrote:
Diagnoses: I assume that the finasteride primarily led to a blockade of the 5-alpha reductase that is encoded for the synthesis of allopregnanolone. This leads to a disruption of the regulation of the GABA receptor, which ultimately leads to the depressive symptoms you described in our initial consultation. The disruption of the GABAergic system is simultaneously associated with a disruption of the glutamatergic system, which explains your lack of motivation. Taking lorazepam [used to treat anxiety disorders] for diagnostic purposes resulted in a dramatic improvement in your symptoms, which ultimately confirms the diagnosis. Under these conditions, you are unable to achieve any academic achievement whatsoever.
• September 2019: Dr. Holler wrote:
His concentration has increased somewhat, but his emotions are still fluctuating… Lorazepam was prescribed as an emergency medication. A visit to the neurologist revealed that all the previous examiners had no idea and couldn’t assess the situation; the values had certainly been measured incorrectly. He then offered him an antidepressant. The patient can certainly do without such therapists. It has now been decided…that neurosteroids will be taken.
The university agreed to postpone his removal from enrollment until June 30, 2020. This means we’ve gained another eight months, which should be enough to improve the situation… The patient supplemented his medical history with information about his drug use: THC regularly, amphetamines and opioids occasionally, and LSD several times.
• October 2019: In his referral to ENT Marcus Zwingmann, MD, internist Selfiraz Dogan, MD, who specializes in pulmonology, wrote:
Sleep Issues: There is a difficulty falling asleep. In the morning after getting up, there is mild sluggishness, as if “weighted down.” Medication History: Previous use of sedatives: patient had taken mirtazapine, but had slept excessively (14 hours) and discontinued it one week ago. No other medications currently taken. Substance Use: Nicotine: irregular use. Alcohol: none.
• December 2019: Dr. Holler wrote:
The patient has what is known as post-finasteride syndrome… Since this diagnosis is not yet guideline-compatible due to the small number of cases, patients are dependent on consulting the few physicians in Germany and Europe who specialize in this syndrome.
• January 2020: Dr. Holler wrote:
The patient complains of bruxism and restless legs at night… A treatment attempt with benserazide [used to treat Parkinson’s disease], was then undertaken. Lorazepam will continue to be prescribed in a smaller amount to raise awareness of the drug’s potential for addiction. The patient has now also begun to lose prescriptions, so it must be assumed that abuse is beginning. He continues to smoke weed.
• March 2020: Dr. Holler wrote:
[T]he patient stated that he had been suffering from diarrhea for 15 and a half weeks. The Restex [levodopa used to treat Parkinson’s disease, and benserazide] has been increased…but the previous results have not been achieved.
• May 2020: Dr. Holler wrote:
No significant improvement after increasing the dosage. The patient has a new primary care physician who would like to contact me by phone. The Restex will probably be replaced with pregabalin [used to treat nerve pain] or gabapentin [used to treat seizure disorders] next week.
• July 2020: Dr. Holler wrote:
A noticeable improvement in alcohol tolerance is noted. He no longer has a hangover after binge drinking, but feels particularly well. He denies the use of other drugs. Nevertheless, in my opinion, there is a significant potential for addiction here, which is precisely the patient’s intention: to be in a “good mood.”
• June 2021: In their referral report to urologist Adrian Tarcau, MD, Michael Zitzmann, MD, and Sabine Kliesch, MD, of the Center for Reproductive Medicine and Andrology wrote:
Reason for consultation: post-finasteride syndrome. Diagnoses: functional hypogonadism, depressive episode, restless legs syndrome, lycopene loss, erectile dysfunction, dissociative sensory and perceptual disorders, chronic fatigue syndrome, exhaustion syndrome, nightmares (anxiety dreams), difficulty falling asleep and staying asleep, non-organic sleep-wake disorder, dysthymia, simple activity and attention disorder, predominantly obsessive thoughts or rumination, anxiety disorder, PANS disorder, nicotine abuse.
The Sorrows of Young and Old Lotfolahpours
On the evening of November 30, 2022, 24-year-old Jalan said goodnight to his parents, Catherine and Mohammad, and retired to his bedroom. Seven months after her son’s death, Catherine contacted the PFS Foundation to put into context what happened next.
“After quitting finasteride in 2019, Jalan started researching PFS. When he learned that his chances of recovery were slim, it came as a shock not only to him, but to our whole family,” she said.
“That was the beginning of a long, difficult period. Each of us reacted differently, though more often than not, we retreated into denial. We were alone, with almost no support from doctors.
“Jalan desperately tried to find another cause for his condition. He underwent nasal surgery, and later had his wisdom teeth removed because of excruciating tension in his jaw. He hoped that might alleviate other PFS symptoms.
“It was hard for us to remain close to him because he was awake mostly at night. He often felt unwell, suffering from severe fatigue, depression, and mood swings. The entire family was overwhelmed. We argued all the time.
“Eventually, Jalan began trying various substances to relieve the unbearable pain that conventional medicine failed to ease.”
On the evening of December 1, 2022, Catherine, who had not seen Jalan all day, peeked into his bedroom. He was lying on the floor, half awake, as if he had choked on something. She called 112.
Jalan was rushed to Sana Klinikum Offenbach, the teaching hospital of Goethe University, where he was intubated and mechanically ventilated—and where he would remain for nine days. Following are excerpts from those charts.
The patient suffers from depression as well as post-finasteride syndrome [and] he has restless legs syndrome. He took finasteride for alopecia. He takes pregabalin and clobazam [used to treat seizure disorders]. His parents had lost contact with their son. They stated that he no longer seemed to know what he was doing.
Diagnoses
1. Drug- or toxin-induced impairment of vigilance
• Urine drug screen: positive for methadone and benzodiazepines
• History: sporadic alcohol and “speed” use
2. Polysubstance dependence, associated with:
• depressive syndrome (possibly related to substance use)
Psychiatry consultation
Marked psychomotor retardation, which partially hinders comprehension; concentration is significantly impaired… Formal thought processes appear organized… expresses anxiety that the current condition may not be transient… No suicidality.
The patient is personally convinced that he is suffering from PFS. He believes that the medication…caused a persistent disruption of his metabolism, thereby rendering him depressed ever since.
He has been studying computer science for three semesters. But he describes the current semester as a “catastrophe,” noting that for months he has lacked drive… The patient is exceptionally well-informed regarding various drugs—including their risks (such as psychosis)—as well as the pharmacology of a wide range of antidepressants. He is clearly intelligent.
The hypothesis of PFS appears questionable overall, particularly regarding persistent effects occurring five years after the last intake of the medication. While it is theoretically possible that a depressive episode triggered by the drug became autonomous and has persisted independently since then, a connection to his irregular, poly-substance drug use is a far more plausible explanation.
Gegen das Schicksal ist kein Kraut (No remedy for fate)
In November 2021, Jalan began seeing neurologist Lilian Faber, MD, and continued to see her until November 2024. Following are excerpts from those charts subsequent to his release from Sana Klinikum:
• January 2023: Dr. Faber wrote:
[T]here is a postural tremor of both hands, slightly predominant on the right side. The cause could be a medication after-effect from previous use of neuroleptics…but with a negative family history.
• July 2023: Dr. Faber wrote:
He had a cold and still feels it. He frequently gets such infections; states that his mitochondria were damaged by taking finasteride, resulting in a disruption of his immune system… His psychiatric therapy has been switched to tianeptine [used to treat MDD]. He…sometimes has this feeling in his face (“like a wave”), as if his eyes were cramping, as if his brain were bleeding, as if there were an “itch in his head,” associated with a feeling of pressure… He suffers from bruxism, and wears a splint.
• November 2023: Dr. Faber wrote:
A drug is approved in the US [zuranolone]…that affects gaba receptors. He has high hopes for this and hopes to reduce his other medications… At 17, he was able to train with positive results, making progress in endurance and strength. Since taking finasteride, citalopram, and mirtrazapine, he has felt worse physically. The drugs triggered restless leg syndrome, and the medications he took for that also caused side effects. He wonders if pregabalin has an addictive effect. This situation prevents him from leading a normal life.
• May 2024: Dr. Faber wrote:
According to the patient, at the start of finasteride treatment, NO relevant pre-existing conditions; during the course of treatment, diagnosis of depression, nicotine 4-5 cigarettes/day on average. Medication: Tianeptine… pregabalin daily, pantoprazole [used to reduce stomach acid] as needed… Tramal [an opioid-like pain medication] had led to an epileptic seizure. Doxepin [a tricyclic antidepressant used to treat MDD]…caused drowsiness so was discontinued… Trimipramine [a tricyclic antidepressant used to treat MDD] caused heavy drowsiness. According to [Dr. Zitzmann’s] medical report, 17 (!) diagnoses.
• November 2024: Dr. Faber wrote:
Everything is the same. He has an exam in three weeks and is having problems studying… He drops glasses because of the tremors… He wanted to apply for disability, but he couldn’t continue studying due to the aforementioned limitations.
Eighty-seven days after his last visit to Dr. Faber, Jalan walked out of the flat he had moved into subsequent to being discharged from Sana Klinikum—half a mile from his parent’s home—and crossed Schäfflestraße.
In the dark of night, he lowered himself onto a bench, never to rise again.
On page one of Jalan’s autopsy, Dr. Plenzig wrote:
Pre-existing conditions included delusional-paranoid disorder, somatization disorders, anxiety disorders, substance abuse, tremor of unclear etiology, medication- or toxin-induced reduced vigilance, polytoxicomania, and post-finasteride syndrome.
All Filed on the Pharma Front
Eighty-three days later, Catherine shared the Lotfolahpour family’s tragedy with Propecia/Proscar maker Organon.
“I hereby report the clear side effects of finasteride on the health of my son,” she wrote, in part. “Initially, he began to get sick noticeably often, including after exercise. When he stopped taking the drug after about two years, countless and unbearable side effects began to appear.”
Six days later, Organon’s Global Safety Department responded, in part:
“As a pharmaceutical company, we are obliged—in the interest of drug safety—to record and follow up on all reports regarding symptoms or medical conditions that occur during or after the use of any of our products. We would also like to ask you to let us know whether the finasteride active ingredient used was our product, ‘Propecia.’ Please find an attached form [Report on Adverse Events Related to Medicinal Products]. We kindly ask that you complete it, or have your physician complete it, and return it to us as soon as possible.”
Catherine reported that Jalan had experienced the following adverse events during and/or post treatment with finasteride 1 mg: life-altering depression, neurological dysfunction, headache tension, tremors, flu-like symptoms, abdominal pain, and fungal infections. She reported as well that the outcome was fatal.
Next, Organon asked Catherine some additional questions, including:
• When did the symptoms of depression first appear? How severe were those symptoms?
• Did your son exhibit symptoms of depression prior to taking Propecia, or were there any risk factors for depressive symptoms, such as: family history of depression; personal history of depressive symptoms or other psychiatric conditions—including alcohol or substance use (if so, which ones?); psychosocial stressors like job loss, family bereavement, or relationship problems; other chronic medical conditions?
The company also asked Catherine for consent to contact the doctor who prescribed finasteride to Jalan, which she granted, and for a copy of the autopsy report.
Catherine thus reiterated to Organon that all Jalan’s symptoms, which grew progressively worse over time, set in after he began taking finasteride, and negatively impacted his studies to a severe extent. In closing, she wrote:
“Prior to this, my son had no history of depression or any other chronic medical conditions, nor were there any psychosocial stressors present in his life. Furthermore, there is no family history of depression.”
On July 1, 2025, Organon thanked Catherine for her assistance and informed her that “We will address any further questions to the primary care physician you have designated.”
On April 29, via email to the company’s Pharmacovigilance Operations Center for Germany, we sought comment from Organon, specifically asking:
(1) Did you contact Dr. Wyrobnik regarding Jalan’s adverse reactions to finasteride? If so, were you able to determine if the doctor ever shared BfArM’s Red Hand Letter with the patient?
(2) Do you share Catherine Béroud’s opinion that finasteride use contributed to her son’s death?
(3) Have any other families in Germany reported the death of a relative that they believe was connected to finasteride use? If so, how many such deaths have been reported, and over what chronological period?
At press time, Organon had not responded to our query.
“For my family, the only good thing that can come out of Jalan’s death will be helping educate the public on finasteride’s many potential dangers,» says Catherine.
«And we hope that will help prevent future deaths.”
If you have a loved one whose death you believe was linked to finasteride use, please email us at ColdCase@pfsfoundation.org.
Finasteride was originally developed by Merck & Co., Inc., and first approved by the US Food and Drug Administration in 1993 as Proscar (5 mg, for enlarged prostate), and again in 1997, as Propecia (1 mg, for hair loss).
In June 2021, Merck spun off its Organon subsidiary as an independent public company (NYSE: OGN). Founded in the Netherlands in 1923, Organon bills itself as a “global health care company dedicated to making a world of difference for women, their families and the communities they care for.” In April 2026, Mumbai, India-based Sun Pharmaceutical Industries agreed to acquire Organon in a deal worth $11.75 billion US.
Among the Merck products Organon acquired in the deal were Proscar and Propecia. To report adverse events for either finasteride product, call the Organon Service Center at (844)674-3200, or email Service_Center@Organon.com.
Anyone living in the US who suffers from PFS should also report his or her symptoms to the US FDA. Anyone living outside the US who suffers from PFS should report his or her symptoms to the US FDA as well as to his or her local DRA, as directed on our Report Your Side Effects page.
If you or a loved one are suffering from PFS, and feeling depressed or unstable, please don’t hesitate to contact the PFS Foundation as soon as possible via our Patient Support hotline: social@pfsfoundation.org
Thank you.